

IFW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))				Docket No. MPI-0003	
In Re Application Of: <b>AMY F. T. ARNSTEN et al.</b>					
Application No. 10/672,626	Filing Date 09/26/2003	Examiner George W. Mitchell	Customer No. 23413	Group Art Unit 1614	Confirmation No. 8080
Title: <b>CHELERYTHRINE, ANALOGS THEREOF AND THEIR USE IN THE TREATMENT OF BIPOLAR DISORDER AND OTHER COGNITIVE DISORDERS</b>					
<p>Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p> <p><b>37 CFR 1.97(b)</b></p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p><b>37 CFR 1.97(c)</b></p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p><b>OR</b></p> <p><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>					

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
MPI-0003

In Re Application of: Amy F. T. Arnsten et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/672,626	09/26/2003	George W. Mitchell	23413	1614	8080

Title: CHELERYTHRINE, ANALOGS THEREOF AND THEIR USE IN THE TREATMENT OF BIPOLAR DISORDER AND OTHER COGNITIVE DISORDERS

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

October 7, 2005

\_\_\_\_\_  
(Date)  
Signature of Person Mailing Correspondence

Janice Young-Astwood

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

Dated: October 7, 2005

\_\_\_\_\_  
Signature

Leslie-Anne Horvath, Ph.D.  
Registration No.: 44,778  
CANTOR COLBURN LLP  
55 Griffin Road South  
Bloomfield, CT 06002  
Telephone: (860) 286-2929  
Facsimile: (860) 286-0115

CC:



MPI-0003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Amy F. T. Arnsten, et al. )  
Serial No.: 10/672,626 ) Group Art Unit: 1614  
Filed: September 26, 2003 ) Before the Examiner:  
George W. Mitchell  
For: CHELERYTHRINE, ANALOGS THEREOF )  
AND THEIR USE IN THE TREATMENT )  
OF BIPOLAR DISORDER AND OTHER )  
COGNITIVE DISORDERS )

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Sir:

In compliance with the duty to disclose, submitted herewith is form PTO-A820 (PTO-1449) listing publication(s) of which those designated by 37 CFR § 1.56 are aware. Copies of the non-United States patents or published applications are enclosed.


The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made, or an admission that the information cited is, or is considered to be, material to patentability.

Respectfully submitted,

CANTOR COLBURN LLP

By: Leslie Anne Horvath  
Leslie-Anne Horvath  
Reg. No. 44,778

Date: October 7, 2005  
Customer No.: 23413  
Telephone: (860) 286-2929

**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*

Docket Number (Optional)

MPI-0003

Application Number

10/672,626

Applicant(s)

Amy F. T. Arnsten et al.

Filing Date

09/26/2003

Group Art Unit

1614

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		US 4,683,133	07/28/1987	Southard			
		US 5,395,615	03/07/1995	Godowski et al.			
		US 5,747,502	05/05/1998	Hanaoka et al.			
		US 5,922,571	07/13/1999	Hillman			

**U.S. PATENT APPLICATION PUBLICATIONS**

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		US 2002/0124272 A1	09/05/2002	Messing et al.			

**FOREIGN PATENT DOCUMENTS**

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
		WO 01/93883 A1	12/13/2001	PCT				

**OTHER DOCUMENTS***(Including Author, Title, Date, Pertinent Pages, Etc.)*

		International Search Report for International Application No. PCT/US04/31567, Mailed on July 14, 2005
		Kaiya, H., "Second Messenger Imbalance Hypothesis of Schizophrenia", Prostaglandins, Leukotrienes, and Essential Fatty Acids 46 (1) 33-8 (1992), Database MEDLINE, PubMed ID 135895

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional) <b>MPI-0003</b>		Application Number <b>10/672,626</b>	
		Applicant(s) <b>Amy F.T. Arnsten</b>			
		Filing Date <b>09/26/2003</b>		Group Art Unit <b>1614</b>	
*EXAMINER INITIAL	<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>				
		Kogan et al., "Long-term glutamate desensitization in locus coeruleus neurons and its role in opiate withdrawal", Brain Research 689 (1995), (1) 111-121			
EXAMINER		DATE CONSIDERED			
<p><b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>					